Head-To-Head Survey: Cellectis (NASDAQ:CLLS) vs. Mosaic ImmunoEngineering (OTCMKTS:CPMV)

Cellectis (NASDAQ:CLLS) and Mosaic ImmunoEngineering (OTCMKTS:CPMV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Cellectis and Mosaic ImmunoEngineering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cellectis	-234.39%	-74.55%	-22.65%
Mosaic ImmunoEngineering	N/A	N/A	-1,371.05%

Earnings & Valuation

This table compares Cellectis and Mosaic ImmunoEngineering”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$9.19 million	9.31	-$101.06 million	($1.30)	-1.18
Mosaic ImmunoEngineering	N/A	N/A	-$1.01 million	($0.15)	-6.60

Mosaic ImmunoEngineering has lower revenue, but higher earnings than Cellectis. Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Cellectis has a beta of 3.06, suggesting that its stock price is 206% more volatile than the S&P 500. Comparatively, Mosaic ImmunoEngineering has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.

Institutional and Insider Ownership

63.9% of Cellectis shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 81.0% of Mosaic ImmunoEngineering shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cellectis and Mosaic ImmunoEngineering, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	0	0	3	0	3.00
Mosaic ImmunoEngineering	0	0	0	0	0.00

Cellectis currently has a consensus price target of $7.00, suggesting a potential upside of 354.55%. Given Cellectis’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cellectis is more favorable than Mosaic ImmunoEngineering.

Summary

Cellectis beats Mosaic ImmunoEngineering on 7 of the 12 factors compared between the two stocks.

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.